JW Pharmaceutical

Diversified pharma

001060 · KOSPI · South Korea

Public Market Listing

001060KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for JW Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
0Approved
5Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Anagliptin(Suiny)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 3
GLP-1 receptorPeptide
ObesityType 2 Diabetes
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Phase 3
Dipeptidyl peptidase-4 (DPP-4)Small molecule
Type 2 Diabetes
Mitiglinide(Glufast)
Phase 3
SUR1 (short-acting)Small molecule
Type 2 Diabetes
LivaloVNo recent activity
Phase 1
HMG-CoA reductase / Angiotensin II type 1 receptorSmall molecule
HypertensionAtherosclerotic Cardiovascular Disease
Preclinical / Unstaged
Undisclosed / early pipelineSmall molecule
Hypertension

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
BofanglutidePhase 3Obesity/Overweight in Adult
Est. primary completion 2027-06-30 · NCT07150975 · CT.gov ↗
What to watch
November 2027 (1)
BofanglutidePhase 3Obstructive Sleep Apnea (OSA)
Est. primary completion 2027-11-14 · NCT07493057 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
BofanglutidePhase 3Obstructive Sleep Apnea (OSA)
Est. primary completion 2028-09-28 · NCT07501832 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 September 2026Licensing dealGZR18 (bofanglutide)Gan & Lee licenses bofanglutide to Menarini for Europe (39 countries)
Gan & Lee Pharmaceuticals; The Menarini Group · Source ↗
12 June 2026Topline resultGZR18GRADUAL-1: bofanglutide meets primary endpoint in China Phase 3
Gan & Lee Pharmaceuticals · Source ↗

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$546M$48M——report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$529M$27M——report ↗
2023-FY$574M$35M——report ↗
2022-FY$532M———report ↗
2021-FY$531M——$1.3Mreport ↗